Hendrickson, Peter G.
Oristian, Kristianne M.
Browne, MaKenna R.
Luo, Lixia
Ma, Yan
Cardona, Diana M.
Nash, Joshua O.
Ballester, Pedro L.
Davidson, Scott
Shlien, Adam http://orcid.org/0000-0002-0368-5370
Linardic, Corinne M.
Kirsch, David G. http://orcid.org/0000-0002-2086-205X
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-22-1-0454)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (7R35CA197616, 1R38CA245204)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
American Society for Radiation Oncology (852948)
Alex’s Lemonade Stand Foundation for Childhood Cancer
Article History
Received: 24 October 2023
Revised: 7 February 2024
Accepted: 14 February 2024
First Online: 27 February 2024
Competing interests
: DGK is a cofounder of and stockholder in XRAD Therapeutics, which is developing radiosensitizers. DGK is a member of the scientific advisory board and owns stock in Lumicell Inc, a company commercializing intraoperative imaging technology. None of these affiliations represents a conflict of interest with respect to the work described in this manuscript. DGK is a coinventor on a patent for a handheld imaging device and is a coinventor on a patent for radiosensitizers. XRAD Therapeutics, Merck, Bristol Myers Squibb, and Varian Medical Systems have provided research support to DGK, but this did not support the research described in this manuscript. The other authors have no conflicting financial interests.